Arbutus Biopharma upgraded by Jefferies with a new price target
$ABUS
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded Arbutus Biopharma from Hold to Buy and set a new price target of $5.00 from $4.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/4/2022 | $5.50 → $6.00 | Buy | Chardan Capital |
| 2/2/2022 | $4.00 → $5.00 | Hold → Buy | Jefferies |
| 11/8/2021 | $7.00 → $9.00 | Market Outperform | JMP Securities |